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Stimulating therapy for obstructive sleep apnoea
The burden of obstructive sleep apnoea (OSA) is increasing due to the worldwide obesity epidemic and the ageing of the population. 1 2 The treatment of OSA is unsatisfactory for some patients since tolerance of the gold standard treatment positive airway pressure (PAP) is quite variable. Among patients who tolerate PAP, results are excellent; however, effectiveness is limited by variable adherence. 3 4 Improvements in our understanding of OSA pathogenesis have led to a concept that the mechanism (endotype) underlying OSA is highly variable across individuals such that some patients have primarily an upper airway anatomical problem, whereas others have dysfunction in upper airway dilator muscles, some have unstable control of breathing and some may have combinations of abnormalities. This realisation has led to the concept of personalised medicine in OSA such that therapies could theoretically be targeted to the mechanism underlying apnoea rather than using a 'one-size-fits-all' approach. 5 Efforts to improve treatment are ongoing by developing new therapeutic approaches (eg, hypoglossal nerve stimulation). 6 7 This approach augments the neural output to upper airway dilator muscles as opposed to 'pneumatically splinting' the airway open in the case of PAP therapy or mechanically enlarging the airway as is done with oral appliance therapy. 8 Strollo et al 9 have demonstrated that phasic unilateral electrical stimulation of the hypoglossal nerve is safe and effective in carefully selected participants with moderate-to-severe OSA, who could not accept or adhere to PAP. The durability of the treatment effect has been sustained up to 36 months. 10 This technology that consists of an implanted pulse generator with sensing and stimulation leads has been approved for commercial use in the USA and Europe.
The report by Pengo 11 in this issue has approached upper airway stimulation in a different manner. These investigators examined the impact of bilateral submental transcutaneous electrical stimulation (TCES) of the upper airway in patients with OSA. This work is an extension of the feasibility study reported by this group in 2011. 12 The authors should be commended for a number of strengths related to this study -rigorous design (randomised sham control), careful measurement of sleep and particularly sleep disruption as well as the assessment of participant symptoms related to TCES. The caveats of this report relate to the fact that the primary outcome (4% oxygen desaturation index) was examined after one night of stimulation in the sleep laboratory, the treatment effect was modest and the active intervention (tonic stimulation) did not impact the apnoea-hypopnoea index in rapid eye movement sleep. 13 A number of questions remain that merit comment: (1) What muscles/muscle groups are being stimulated? The upper airway has 23 different pairs of muscles with considerable complexity ( phasic vs tonic, protruders vs retractors, etc); thus, further efforts will be required regarding precise mechanisms of surface stimulation. (2) What patient endotype responds best to TCES? Considerable work is ongoing suggesting only a subset of patients with OSA have a major issue with upper airway dilator muscle function. 14 15 Thus, one might predict that efforts to augment hypoglossal motor output may be more effective for some patients than for others with OSA depending on underlying mechanism. 15 (3) Is bilateral stimulation and opposition to unilateral stimulation the better approach? Clinical trials will be required to compare these approaches, although physiological studies (eg, comparing unilateral vs bilateral stimulation on pharyngeal mechanics) would also be valuable in addressing this question. (4) Can one night of treatment with this device refine selection for implantable systems? Such an approach might allow clinicians to determine a priori which patients should undergo the risk and expense of an implantable nerve stimulator. (5) If TCES is used as a stand-alone treatment, what is the long-term impact on sleep, sleep disordered breathing, patient symptoms (ie, snoring, sleepiness and quality of life), patient acceptance/ adherence and long-term cardiovascular/ metabolic risk? 16 17 While the overall response to TCES was modest, it is conceivable that refining the patient selection by identifying endotypes that might respond to this therapy would strengthen the value of this approach. Future work could possibly incorporate drug-induced sedation endoscopy to examine favourable patterns of airway collapse 9 or assessment of the physiologic signature of airflow. 18 19 Such approaches could help to identify those patients with dysfunction in upper airway dilator muscle control who may be responsive to stimulation approaches. On the other hand, patients with OSA with an issue primarily of unstable ventilatory control or low arousal threshold may be predicted to fail treatment targeted just at upper airway dilator muscles. 14 20 We applaud the authors for moving forward our understanding of electrical stimulation of the upper airway and fuelling further research in this area.
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